CN706: Phase I/II

In a U.S. Phase I/II trial of 20 men who had failed radiation therapy, PSA levels decreased from baseline in 9 of 11 patients in the 2 highest dose groups. Of those 9, 4 patients had a partial PSA response (?50 percent reduction in PSA for at least 4 weeks), and the partial response lasted at least 9 months in 3 of those patients. No significant adverse events were noted at any of the 5 dose levels, and adenoviral replication was observed in tissue samples. Data were presented at the American Society for Therapeutic Radiology and Oncology conference in Boston. ...